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We present an easy-to-use, open-source Optimised Exome analysis tool, OpEx (http://icr.ac.uk/opex) 
that accurately detects small-scale variation, including indels, to clinical standards. We evaluated 
OpEx performance with an experimentally validated dataset (the ICR142 NGS validation series), a 
large 1000 exome dataset (the ICR1000 UK exome series), and a clinical proband-parent trio dataset. 
The performance of OpEx for high-quality base substitutions and short indels in both small and large 
datasets is excellent, with overall sensitivity of 95%, specificity of 97% and low false detection rate 
(FDR) of 3%. Depending on the individual performance requirements the OpEx output allows one 
to optimise the inevitable trade-offs between sensitivity and specificity. For example, in the clinical 
setting one could permit a higher FDR and lower specificity to maximise sensitivity. In contexts 
where experimental validation is not possible, minimising the FDR and improving specificity may 
be a preferable trade-off for slightly lower sensitivity. OpEx is simple to install and use; the whole 
pipeline is run from a single command. OpEx is therefore well suited to the increasing research and 
clinical laboratories undertaking exome sequencing, particularly those without in-house dedicated 
bioinformatics expertise.
Exome sequencing is becoming a standard method used by increasingly diverse research and clinical laboratories. 
Unfortunately, easy-to-use, open-source exome analytical pipelines are not readily available, and most laborato-
ries therefore implement bespoke pipelines1. There is wide variability in these underlying approaches and per-
formance of analytical tools, and different versions of individual tools are often concurrently available, impeding 
standardisation and cross-validation. This is further exacerbated by the limited pipeline performance validation 
typically undertaken, particularly with respect to indel calling and specificity of pipelines, which are both vitally 
important for clinical exome sequencing. A further challenge for the clinical setting is the requirement to analyse 
large numbers of samples for optimal performance under the joint calling approach recommended by the most 
widely used software suite, GATK2. This is often not possible for clinical pipelines, where the need for fast test 
results necessitates analyses of smaller numbers of samples.
OpEx Description
To address these issues we created the OpEx (Optimised Exome) analysis tool. OpEx includes a fixed implemen-
tation of tools for read alignment, variant calling and annotation optimised for individual or multiple exome 
sequencing analysis, outputting data to clinical standards. We specifically focused on making OpEx simple to 
install and to use; the whole pipeline is run with a single command. It is therefore well suited to the increasing 
number of research and clinical laboratories without in-house dedicated exome bioinformatic expertise. An over-
view of OpEx is given below. Full details of OpEx are given in the Supplementary Appendix and are available at 
www.icr.ac.uk/opex.
OpEx takes the raw FASTQ files generated by paired-end Illumina sequencing as its input, which are mapped 
to the human reference genome using Stampy with BWA for premapping3,4. A custom Python script then per-
forms BAM sorting and indexing. Duplicate reads are marked with Picard (http://picard.sourceforge.net). We 
developed CoverView to provide the quality control information required in clinical laboratories. CoverView 
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provides coverage, base quality and mapping quality metrics. CoverView utilises the user-supplied BED file 
and Ensembl transcripts to output the target regions which failed to achieve good quality coverage and anno-
tates these regions according to their location in the gene transcript (e.g. c.1500–1550 of BRCA1). This seamless 
transcript-based annotation is particularly useful for the many laboratories that use orthogonal methods, such as 
Sanger sequencing, to ‘fill-in’ areas that fail to reach the required coverage threshold.
Within OpEx we provide a default transcript set which includes the Locus Reference Genomic (LRG) 
sequences to facilitate clinical utility5. However, users can specify any Ensembl transcripts, including the entire 
set of available transcripts, if preferred. For the default transcript we used BioMart to obtain a list of all known 
protein-coding transcripts. There were 83,331 different protein-coding transcripts corresponding to 20,228 genes. 
We selected the 19,922 genes present on chromosomes 1–22, X, or Y, that had both a start and stop codon, and 
were not known pseudogenes. 74% of these genes (n = 14,830) had more than one transcript. We selected a single 
transcript for these genes with preference for a CCDS transcript according to Supplementary Figure 1. The spe-
cific transcripts selected are given in Supplementary Table 1.
OpEx uses Platypus for variant calling6. Usefully, Platypus provides equivalent performance irrespective of the 
number of exomes being analysed. Analysis of many samples can thus be parallelised with no reduction in calling 
performance. Platypus also calls base substitutions and indels simultaneously. This rapid independent variant 
calling approach enables analysis to keep pace with the sequencing output, allowing early assessment of potential 
sample quality issues which are not detectable through the CoverView coverage metrics, e.g. a contaminated 
sample showing excess heterozygosity. It also provides early opportunities to assess and act on variant data, for 
example allowing early identification of a disease-causing variant in a plausible candidate gene. These give OpEx 
a useful advantage over callers that need to call across all samples together to provide optimal performance and 
thus cannot be run until all laboratory work for all exomes is complete. Of note, OpEx uses Platypus v0.1.5 for 
variant calling. We selected this version due to its mutually exclusive calling of a variant as either a base substitu-
tion or a simple insertion or deletion of sequence. Later versions of Platypus merge nearby base substitutions on 
the same allele into a single complex indel that does not change the length of the DNA sequence, requiring further 
bespoke code to recover the constituent variants for comparison with other data. Because the OpEx code is freely 
available, users have the flexibility to use different versions of any OpEx software component, including other 
versions of Platypus. However, it cannot be assumed that other versions will have exactly the same performance 
as reported here.
OpEx next uses CAVA to annotate variants7. Importantly, CAVA provides consistent annotation of indels, 
which is often suboptimal in annotation tools. Indel calling is challenging because there are often multiple equally 
correct ways of representing the indel in the standard VCF format exported from next generation sequencing 
(NGS) pipelines, many of which are inconsistent with clinical annotation conventions7. CAVA consistently pro-
vides the clinically appropriate indel call. Additionally, if an indel has an alternative representation, the most 3′ 
and the most 5′ annotations are outputted to facilitate appropriate investigation of the functional and/or clinical 
consequences.
Finally OpEx performs a parsing step using a custom Python script which assigns a high/low quality flag, 
removes intergenic calls, and returns an easily readable tab-separated output. Base substitutions are flagged as 
high quality if the Platypus QUAL score is at least 100. Indels are flagged as high quality if both the variant allele 
proportion (calculated from the TR/TC) is at least 0.2 and the Platypus FILTER value is PASS. OpEx then returns 
a simple tab-separated text file containing all variants occurring in the user-supplied transcripts.
OpEx provides standardised variant and coverage files but also allows flexibility for users to customise the 
default settings. OpEx also outputs useful interim files, such as the BAM file and the raw VCF file. Additionally, 
OpEx can output the variant file in VCF, allowing further downstream annotation, for example, with tools that 
predict variant functional/clinical impact8–10.
OpEx evaluation. To evaluate OpEx performance we first analysed the ICR142 NGS validation series, which 
includes exome sequence FASTQ files for 142 samples together with Sanger sequencing data at 730 sites11. OpEx 
was run using one CPU per exome. Because samples are analysed independently, runtimes are limited only by 
the number of CPUs available and the size of the FASTQ file. The 142 samples had an average of 70 M reads in the 
input FASTQ files (range 30 M–159 M), resulting in an overall average runtime of 35 hours (range 17–101 hours). 
All 142 were run simultaneously, thus the actual runtime for the series was 101 hours. Faster runtimes would 
be possible with multithreading. Alignment constituted the majority of the runtime (69–88%), followed by the 
CoverView coverage evaluation (6–18%), though this could be reduced if evaluation is restricted to select genes, a 
common approach in clinical exome analysis. Variant calling and annotation comprised a very small proportion 
of runtime (0.4–1.6%) due to the rapid performance of Platypus and CAVA.
The ICR142 NGS validation series contains Sanger sequencing data for both positive and negative sites, with a 
particular focus on indels, allowing assessment of specificity as well as sensitivity for indels. Four of the 730 vari-
ant sites with Sanger data were in transcripts not included in the default OpEx database and were excluded. All of 
the remaining 726 sites had at least 15x coverage in the exome data, defined as at least 15 reads of good mapping 
quality (mapping score ≥ 20). We classified base substitutions as detected if the exact base change was called by 
OpEx. For indels, we also included the seven complex indels that were called by OpEx but annotated slightly 
differently from the Sanger call as having been detected. The evaluated sites are given in Supplementary Table 2. 
Length of indel impacted performance. For short indels, which we define here as being ≤ 10 bp, the sensitivity was 
96% (258/269) and the false detection rate (FDR) was 6% (15/273). However, for longer indels, > 10 bp, the FDR 
was much higher at 50% (16/32) though the sensitivity remained high 94% (16/17). As there were so few exam-
ples of this rare variant class with which to evaluate performance, we excluded indels > 10 bp in our performance 
evaluation below, in which ‘all calls’ refers to all base substitutions and indels ≤ 10 bp.
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The overall sensitivity of all calls was 97%, specificity was 90% and FDR was 8%. Using only the high-quality 
calls improved the specificity (97%) and FDR (3%) with a marginal reduction of sensitivity (95%). Sensitivity for 
base substitutions was excellent in both the all call set and the high-quality call set, but the specificity was mark-
edly improved in the high-quality call set (from 60% to 96%). The indel calling performance was good, with over-
all sensitivity of 96%, specificity of 95% and FDR of 6% in the all call set. Using only high-quality calls, specificity 
(97%) and FDR (4%) of indel calls were improved, but there was some reduction in sensitivity (93%) (Table 1).
The eleven missed indels were explicable by the sequence context or quality: four were deletions in long 
homopolymer tracts, four were in regions with poor mapping quality, two had > 25% of reads with poor base 
quality, and one was in a simple repeat (Supplementary Table 3). Thus it is possible to predict, and potentially flag, 
regions in which indel calling may be suboptimal, due to well-recognised limitations of short-read NGS data. 
Importantly, the nine false indel calls in the high-quality call set are all present in both the Exome Variant Server 
and ExAC databases, suggesting they may represent pipeline-independent artefacts of NGS analysis12,13.
Depending on the individual performance requirements the OpEx output allows one to optimise the inevita-
ble trade-offs between sensitivity and specificity. For example, in the clinical setting one often tolerates a higher 
FDR and lower specificity to maximise sensitivity. In contexts where experimental validation is not possible, 
minimising the FDR and improving specificity is often an acceptable trade-off for slightly lower sensitivity.
We next applied OpEx to a large-scale dataset, the ICR1000 UK exome series, to better evaluate OpEx per-
formance in detection of rare variation14. We selected 116 sites at which OpEx detected a variant in only one 
individual in the ICR1000 UK exome series, to evaluate performance at rare variation. Variant sites were validated 
by Sanger sequencing. The sites included 31 base substitutions, 36 deletions and 49 insertions. The 31 base substi-
tutions, 13 of the deletions, and two of the insertions occurred in genes for which we already had Sanger sequenc-
ing primers in-house. The remaining 23 deletions and 47 insertions were selected randomly from amongst 96 
individuals whose DNA was present on the same plate, to aid the laboratory work. OpEx performance was again 
excellent, with 97% sensitivity (31/31 base substitutions, 35/36 deletions, 47/49 insertions) and FDR of 3% (0/31 
base substitutions, 1/36 deletions, 2/49 insertions). The three false positive variants were explicable by poor data 
quality: two were insertions of 6 bp and 8 bp present at the end of reads (a common site of false positive calls) and 
one was a 3 bp deletion in a region with poor mapping quality and poor coverage.
Platypus’s superior FDR in comparison with popular variant callers with similar sensitivities, such as GATK 
and samtools, has been previously reported6. The excellent sensitivities and FDRs we observed in both the 
ICR1000 and ICR142 series further support these data. Additionally, use of CAVA returned exactly matching 
annotations for indels when compared with the Sanger data, an advantage over other popular annotation tools, 
as previously described7.
Finally we tested OpEx performance in a proband-parent trio exome sequencing dataset to detect de novo 
variation, one of the commonest uses of clinical exome sequencing15. We used exome data from a trio in which 
the proband has an overgrowth syndrome due to a de novo indel mutation c.933_934insTCTT in DNMT3A16. 
We used a Python script to first identify all variant sites in the proband which were not present in either parent 
and then generated the coverage at these sites in both parents using CoverView. A variant was a candidate de 
novo variant if the quality flag was “high”, the TC value was at least 15x, and the coverage was at least 15x in 
both parents. Protein-altering variants were defined as those with CAVA class NSY, EE, IF, ESS, SG, or FS and 
those variants with CAVA class ESS, SG, or FS were further defined as protein-truncating7. Comparison of the 
proband and parental data highlighted 27 candidate de novo protein-altering variants, of which only two were 
protein-truncating variants, one of which was the DNMT3A mutation. The analysis was completed in 33 hours.
Summary. OpEx is simple to install and can be run with a single command and input FASTQ files. The 
software is open source and freely available for download at www.icr.ac.uk/opex or at https://github.com/
RahmanTeam/OpEx. The individual components of the pipeline are also freely available. Our detailed 
Variant type All calls High quality calls
Sensitivity
Overall* 378/389 (97%) 368/389 (95%)
Base substitutions 120/120 (100%) 117/120 (98%)
All indels 274/286 (96%) 266/286 (93%)
Short indels 258/269 (96%) 251/269 (93%)
Long indels 16/17 (94%) 15/17 (88%)
Specificity
Overall* 288/320 (90%) 309/320 (97%)
No base substitution present 27/45 (61%) 43/45 (96%)
No indel present (short only) 261/275 (95%) 266/275 (97%)
No indel present (short and long) 245/275 (89%) 260/275 (95%)
False detection rate
Overall* 32/410 (8%) 11/379 (3%)
Base substitutions 18/138 (13%) 2/119 (2%)
All indels 32/307 (10%) 15/281 (5%)
Short indels 15/273 (6%) 9/260 (4%)
Long indels 16/32 (50%) 6/21 (29%)
Table 1.  OpEx variant calling performance in ICR142 NGS validation series. * Overall numbers exclude 
long indels.
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documentation, the availability of the OpEx source code, and the availability of the ICR142 and ICR1000 datasets 
allow users of other open-source frameworks to fully replicate and evaluate our pipeline in-house. However, we 
believe the primary advantage of OpEx is as a fully developed validated pipeline requiring minimal user input 
and no specialised informatic expertise. Due to its excellent performance and suitability for clinical and research 
settings, OpEx is now our standard pipeline for all exome analyses.
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